Home
/
ROCKET PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
ROCKET PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ROCKET PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q2
2025
Jun 30, 2025
$0
Aug 7, 2025
Q1
2025
Mar 31, 2025
$0
May 8, 2025
Q3
2025
Sep 30, 2024
$0
Nov 6, 2025
Q2
2025
Jun 30, 2024
$0
Aug 7, 2025
Q1
2025
Mar 31, 2024
$0
May 8, 2025
Q3
2024
Sep 30, 2023
$0
Nov 7, 2024
Q2
2024
Jun 30, 2023
$0
Aug 6, 2024
Q1
2024
Mar 31, 2023
$0
May 7, 2024
Q3
2023
Sep 30, 2022
$0
Nov 7, 2023
Q2
2023
Jun 30, 2022
$0
Aug 9, 2023
Q1
2023
Mar 31, 2022
$0
May 5, 2023
Q3
2022
Sep 30, 2021
$0
Nov 4, 2022
Q2
2022
Jun 30, 2021
$0
Aug 9, 2022
Q1
2022
Mar 31, 2021
$0
May 6, 2022
Q3
2021
Sep 30, 2020
$0
Nov 5, 2021
Q2
2021
Jun 30, 2020
$0
Aug 9, 2021
Q1
2021
Mar 31, 2020
$0
May 10, 2021
Q3
2020
Sep 30, 2019
$0
Nov 6, 2020
Q2
2020
Jun 30, 2019
$0
Aug 5, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$0
May 11, 2018
Q1
2018
Mar 31, 2017
$0
May 11, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($50.33M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($68.92M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($68.92M)
Aug 7, 2025
Q2
2025
Mar 31, 2025
($61.33M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
($61.33M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($61.33M)
May 8, 2025
Q3
2025
Sep 30, 2024
($66.72M)
Nov 6, 2025
Q3
2025
Jun 30, 2024
($69.65M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($69.65M)
Aug 7, 2025
Q2
2025
Mar 31, 2024
($62.05M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($62.05M)
May 8, 2025
Q3
2025
Mar 31, 2024
($62.05M)
Nov 6, 2025
Q3
2024
Sep 30, 2023
($61.90M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($65.70M)
Aug 6, 2024
Q3
2024
Jun 30, 2023
($65.70M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($58.34M)
May 7, 2024
Q2
2024
Mar 31, 2023
($58.34M)
Aug 6, 2024
Q3
2024
Mar 31, 2023
($58.34M)
Nov 7, 2024
Q3
2023
Sep 30, 2022
($57.76M)
Nov 7, 2023
Q3
2023
Jun 30, 2022
($54.40M)
Nov 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($52.25M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($71.15M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($64.39M)
May 8, 2025
Q3
2025
Sep 30, 2024
($69.42M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($73.71M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($67.38M)
May 8, 2025
Q3
2024
Sep 30, 2023
($65.43M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($68.76M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($62.19M)
May 7, 2024
Q3
2023
Sep 30, 2022
($58.49M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($54.21M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($42.56M)
May 5, 2023
Q3
2022
Sep 30, 2021
($49.65M)
Nov 4, 2022
Q2
2022
Jun 30, 2021
($34.05M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($39.22M)
May 6, 2022
Q3
2021
Sep 30, 2020
($27.39M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($23.56M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($24.12M)
May 10, 2021
Q3
2020
Sep 30, 2019
($19.17M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($18.39M)
Aug 5, 2020